The protein induced by vitamin K absence or antagonists-II (PIVKA-II) or Decarboxy-Prothrombine (DCP) test is used as a tumor marker to aid in the diagnosis of hepatocellular carcinoma (HCC). HCC is a primary malignancy of the liver and occurs predominantly in patients with underlying chronic liver disease and cirrhosis. Liver cancer grows silently with mild or no symptoms until advanced. In the absence of an effective treatment for advanced stage of hepatic cancer, hope lies in early detection and screening for high-risk population.